VARTUTRACE (VTP-01/VTP-02)

About Var2 Pharmaceuticals

Var2 Pharmaceuticals is pioneering a novel oncology platform based on targeting oncofetal chondroitin sulfate (ofCS), a carbohydrate modification expressed in over 95% of cancers but absent in most healthy tissues. Its lead assets, called Vartumabs, are proprietary antibodies with high affinity for ofCS, being developed in multiple formats including antibody-drug conjugates (ADCs), bispecifics, and cell therapies. The company is clinical-stage, having initiated a Phase 0 imaging trial in late 2024 and planning a Phase I/IIA trial for its lead ADC candidate in 2027.

Therapeutic Areas